Pfizer (NYSE:PFE) reported Phase 2b results for its GLP-1 anti-obesity candidate, PF-08653944, showing potential for a once ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Pfizer’s GLP-1 weight management treatment Xianweiying, is reportedly available for pre-order in China in the wake of ...

Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...

(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the ...

April 20 (Reuters) - Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will ...

Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks for beginners to invest in. CICC initiated coverage of Pfizer Inc.

This podcast comes from the DPHARM 2025 meeting. Pfizer details how they jointly co-designed and implemented an EDC/CDMS platform that’s fit for purpose. This session focuses on: Engaging all ...